No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
BCLI Brainstorm Cell Therapeutics
- 0.378
- -0.162-30.04%
Close Apr 30 16:00 ET
- 0.414
- +0.037+9.67%
Post 16:27 ET
25.80MMarket Cap-943P/E (TTM)
0.559High0.357Low1.73MVolume0.540Open0.540Pre Close782.64KTurnover2.84%Turnover RatioLossP/E (Static)68.34MShares3.34052wk High-5.32P/B22.95MFloat Cap0.13452wk Low--Dividend TTM60.80MShs Float52.500Historical High--Div YieldTTM37.38%Amplitude0.134Historical Low0.453Avg Price1Lot Size
Post-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Brainstorm Cell Therapeutics Executive Leadership Changes
BrainStorm Cell Therapeutics Promotes Bob Dagher to Chief Medical Officer
Reported Earlier, BrainStorm Cell Therapeutics Announces Management Changes As It Plans Registrational Phase 3b Trial Of NurOwn
Bob Dagher, MD, Promoted to Chief Medical OfficerDr. Stacy Lindborg Stepping Down as Co-CEO and Transitioning to Board of Directors
BrainStorm Cell Therapeutics Loses Co-CEO Lindborg, Names Dagher as New Medical Chief
By Ben Glickman BrainStorm Cell Therapeutics named a new medical chief and said Co-Chief Executive Stacy Lindborg would step down ahead of a long-awaited clinical trial. The New York-based company,
BrainStorm Cell Therapeutics: Bob Dagher, MD, Promoted to Chief Medical Officer >GHDN.BE
BrainStorm Cell Therapeutics: Bob Dagher, MD, Promoted to Chief Medical Officer >GHDN.BE
BrainStorm Cell Therapeutics: Dr. Stacy Lindborg Stepping Down as Co-CEO and Transitioning to Board of Directors >GHDN.BE
BrainStorm Cell Therapeutics: Dr. Stacy Lindborg Stepping Down as Co-CEO and Transitioning to Board of Directors >GHDN.BE
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg